Advertisement

Drug Safety

pp 1–10 | Cite as

Use of FDA’s Sentinel System to Quantify Seizure Risk Immediately Following New Ranolazine Exposure

  • Efe EworukeEmail author
  • Emily C. Welch
  • Anne Tobenkin
  • Judith C. Maro
Original Research Article
  • 35 Downloads

Abstract

Introduction

Neurological complications including seizures have been reported with ranolazine. We sought to quantify the risk of seizure-related hospitalizations or emergency department events following ranolazine exposure in the Sentinel System (2006–2015).

Study Design and Setting

Eligibility criteria were new use of ranolazine after 183 days washout period and absence of seizure diagnoses, anti-epileptic drugs, or seizure-related disorders during the baseline period.

Results

Among 52,155 ranolazine users, we identified 28 seizures in the 1–32 days after new ranolazine dispensing: 12 occurring in days 1–10 (high-risk window), 11 in days 11–20 (moderate-risk window) and 5 in the control window (days 21–32). Assuming an equal likelihood of seizure events across the 32-day observation window, we estimate an attributable risk of 0.9 excess cases per 10,000 exposed users. Using a self-controlled risk interval design with exact logistic regression, seizures were elevated in the high-risk window (relative risk [RR] 2.88 (95% confidence interval [CI] 1.01–8.33) compared with the control window. No significant increased risk was observed in the moderate window. Half of the seizure cases had a diagnosis of renal disease, although seizure risk was not significant (RR 3.20 [CI 0.82–14.01]). A majority of patients in both risk windows were 75 years or older.

Conclusion

Our study suggests risk among younger ranolazine patients is rare. Given the imprecision of the risk estimates, we interpret the elevated seizure risk following ranolazine exposure with caution. Further analysis in a larger elderly population is warranted.

Notes

Acknowledgements

The views expressed in this paper are those of the authors and are not intended to convey official US Food and Drug Administration policy or guidance. Many thanks to the Data Partners who provided data used in the analysis: Aetna, Blue Bell, PA; Blue Cross Blue Shield of Massachusetts, Boston, MA; Harvard Pilgrim Health Care Institute, Boston, MA; HealthCore, Inc., Translational Research for Affordability and Quality, Alexandria, VA; HealthPartners Institute, Minneapolis, MN; Humana, Inc., Comprehensive Health Insights, Miramar, FL; Kaiser Permanente Colorado Institute for Health Research, Denver, CO; Kaiser Permanente Center for Health Research Hawai’i, Honolulu, HI; Kaiser Permanente Mid-Atlantic States, Mid-Atlantic Permanente Research Institute, Rockville, MD; Kaiser Permanente Northern California, Division of Research, Oakland, CA; Kaiser Permanente Northwest Center for Health Research, Portland, OR; Kaiser Permanente Washington Health Research Institute, Seattle, WA; OptumInsight Life Sciences Inc., Boston, MA; Vanderbilt University Medical Center, Department of Health Policy, Nashville, TN, through the Tennessee Division of TennCare of the Department of Finance and Administration, which provided data. Many thanks to Andrew Petrone for programming support and Nicole Haug for analytic support.

Compliance with Ethical Standards

Conflict of interest

Efe Eworuke has no conflicts of interest that are directly relevant to the content of this study. Emily C. Welch has no conflicts of interest that are directly relevant to the content of this study. Anne Tobenkin has no conflicts of interest that are directly relevant to the content of this study. Judith C. Maro has no conflicts of interest that are directly relevant to the content of this study.

Funding

This project was supported by Task Order HHSF22301012T under Master Agreement Health and Human Services: HHSF223201400030I from the US Food and Drug Administration (FDA).

Supplementary material

40264_2019_798_MOESM1_ESM.pdf (244 kb)
Supplementary material 1 (PDF 244 kb)

References

  1. 1.
    Ball R, Robb M, Anderson SA, Dal Pan G. The FDA’s sentinel initiative—a comprehensive approach to medical product surveillance. Clin Pharmacol Ther. 2016;99(3):265–8.CrossRefGoogle Scholar
  2. 2.
    Curtis LH, Weiner MG, Boudreau DM, Cooper WO, Daniel GW, Nair VP, et al. Design considerations, architecture, and use of the Mini-Sentinel distributed data system. Pharmacoepidemiol Drug Saf. 2012;21(Suppl 1):23–31.CrossRefGoogle Scholar
  3. 3.
    Center SO. Routine Querying Systems: Cohort Identification and Descriptive Analysis: Self-controlled Risk Interval Design [cited 2018 3/27/2018]. https://www.sentinelinitiative.org/sentinel/surveillance-tools/routine-querying-tools/routine-querying-system. Accessed 20 Apr 2018.
  4. 4.
    Temple R. NDA Approval Letter for Ranolazine. In: Services UDoHaH, editor. 2006.Google Scholar
  5. 5.
    Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012;126(25):e354–471.Google Scholar
  6. 6.
    Chaitman BR, Skettino SL, Parker JO, Hanley P, Meluzin J, Kuch J, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004;43(8):1375–82.CrossRefGoogle Scholar
  7. 7.
    Jerling M. Clinical pharmacokinetics of ranolazine. Clin Pharmacokinet. 2006;45(5):469–91.CrossRefGoogle Scholar
  8. 8.
    Tobenkin A. Pharmacovigilance Review of Ranolazine and Seizure Risk. In: Division of Pharmacovigilance OoPaE, Office of Surveillance and Epidemiology, editor. 2016.Google Scholar
  9. 9.
    Kalra SS, Arora Z, Nielsen C. Ranolazine and hallucinations. 2017.Google Scholar
  10. 10.
    Mishra A, Pandya HV, Dave N, Mathew M, Sapre CM, Chaudhary S. A rare debilitating neurological adverse effect of ranolazine due to drug interaction with clarithromycin. Indian J Pharmacol. 2014;46(5):547–8.CrossRefGoogle Scholar
  11. 11.
    Porhomayon J, Zadeii G, Yarahmadi A. A rare neurological complication of ranolazine. Case Rep Neurol Med. 2013;2013:451206.Google Scholar
  12. 12.
    Southard RA, R MB, Bui AH, Blankstein R. Neurologic adverse effects of ranolazine in an elderly patient with renal impairment. Pharmacotherapy. 2013;33(1):e9–e13.Google Scholar
  13. 13.
    Jarecki BW, Piekarz AD, Jackson JO 2nd, Cummins TR. Human voltage-gated sodium channel mutations that cause inherited neuronal and muscle channelopathies increase resurgent sodium currents. J Clin Invest. 2010;120(1):369–78.CrossRefGoogle Scholar
  14. 14.
    Thyagarajan V, Su S, Gee J, Duffy J, McCarthy NL, Chan KA, et al. Identification of seizures among adults and children following influenza vaccination using health insurance claims data. Vaccine. 2013;31(50):5997–6002.CrossRefGoogle Scholar
  15. 15.
    Glanz JM, McClure DL, Xu S, Hambidge SJ, Lee M, Kolczak MS, et al. Four different study designs to evaluate vaccine safety were equally validated with contrasting limitations. J Clin Epidemiol. 2006;59(8):808–18.CrossRefGoogle Scholar
  16. 16.
    Greene SK, Kulldorff M, Lewis EM, Li R, Yin R, Weintraub ES, et al. Near real-time surveillance for influenza vaccine safety: proof-of-concept in the Vaccine Safety Datalink Project. Am J Epidemiol. 2010;171(2):177–88.CrossRefGoogle Scholar
  17. 17.
    Greene SK, Rett M, Weintraub ES, Li L, Yin R, Amato AA, et al. Risk of confirmed Guillain-Barre syndrome following receipt of monovalent inactivated influenza A (H1N1) and seasonal influenza vaccines in the Vaccine Safety Datalink Project, 2009-2010. Am J Epidemiol. 2012;175(11):1100–9.CrossRefGoogle Scholar
  18. 18.
    Klein NP, Hansen J, Lewis E, Lyon L, Nguyen B, Black S, et al. Post-marketing safety evaluation of a tetanus toxoid, reduced diphtheria toxoid and 3-component acellular pertussis vaccine administered to a cohort of adolescents in a United States health maintenance organization. Pediatr Infect Dis J. 2010;29(7):613–7.CrossRefGoogle Scholar
  19. 19.
    Noel G, Minodier P, Merrot T. Intussusception risk after rotavirus vaccination in U.S. infants. N Engl J Med. 2014;370(18):1766.Google Scholar
  20. 20.
    Kulldorff M. A spatial scan statistic. Commun Stat Theory Methods. 1997;26(6):1481–96.CrossRefGoogle Scholar
  21. 21.
    Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011;64(7):749–59.CrossRefGoogle Scholar
  22. 22.
    McGraw D, Rosati K, Evans B. A policy framework for public health uses of electronic health data. Pharmacoepidemiol Drug Saf. 2012;21(Suppl 1):18–22.CrossRefGoogle Scholar
  23. 23.
    Results of Sentinel query. Available at: https://www.sentinelinitiative.org/drugs/assessments/ranexa-ranolazine-and-seizures. Accessed 18 Jan 2019.

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Division of Epidemiology II, Office of Pharmacovigilance and Epidemiology, Office of Surveillance and EpidemiologyCenter for Drug Evaluation and Research, Food and Drug AdministrationSilver SpringUSA
  2. 2.Department of Population MedicineHarvard Pilgrim Health Care InstituteBostonUSA
  3. 3.Division of Pharmacovigilance, Office of Pharmacovigilance and Epidemiology, Office of Surveillance and EpidemiologyCenter for Drug Evaluation and Research, Food and Drug AdministrationSilver SpringUSA

Personalised recommendations